ZIRCON Phase 3 IND Submitted to the US FDA
Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx
Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3 Investigational New Drug (IND) application to the United States Food and Drug Administration for TLX250-CDx (89Zr-girentuximab, for the imaging of renal cancer with Position Emission Tomography) as part of the international Phase 3 ZIRCON study.
The ZIRCON study is expected to commence enrolling US patients in Q1 2020.
To read the full media release please click here.